Thanks for your reply Dew. Your judgement and knowledge on these and other biotechs appears very grounded.
It is interesting that DNDN seems to be drifting down from its momentary pop on the ASCO news to the $6.4 range. Many on the crazy yahoo DNDN message board point out that options expiration this coming Friday may be having some affect on the share price. There are a lot of open contracts from the 5.0 to 10.0 strikes, with heaviest open interest at $7.5 strike. Nonetheless, DNDN seems to be drifting very slowly down towards the mid-$5's range. Also of interest is that its been holding a very steady price during most of the day after noon. Some have even said it appears to be "collared", where market makers or traders are sort of controlling the action.
I would like to see some steady accumulation by fund managers and institutions over the next few months, at least to show confidence in what DNDN has accomplished to date with their trials of Provenge.
Thanks for any other thoughts or news you can dig up on DNDN.
Thanks also to walldiver regarding his thoughts on CELL GENESYS and other DNDN competitors.
Cheers, Spartex
